Femasys Inc.

NasdaqCM FEMY

Femasys Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 28.86%

Femasys Inc. Gross Profit Margin is 28.86% for the Trailing 12 Months (TTM) ending September 30, 2024, a -55.31% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Femasys Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 64.57%, a -1.69% change year over year.
Femasys Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 65.69%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: FEMY

Femasys Inc.

CEO	Ms. Kathy Lee-Sepsick M.B.A.
IPO Date	June 18, 2021
Location	United States
Headquarters	3950 Johns Creek Court
Employees	32
Sector	Healthcare
Industries Biotechnology 3D Printing Cleaning Supplies Clinical Trials Cosmetics Medical Instruments Personal Care Pharmaceuticals

Description

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Key trends

Past 5 years